Physician profile
Patricia Dinger
NPI 1770709370
$15,074.28
in general payments reported to CMS, 2019-2025
40 companies · $3,301 in 2025
The $3,301 reported for 2025 was more than what 80% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,138 · 2020: $1,342 · 2021: $1,982 · 2022: $2,432 · 2023: $2,293 · 2024: $2,586 · 2025: $3,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,990 · Education: $101 · Consulting Fee: $89.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,989.53 |
| Education | $101.34 |
| Consulting Fee | $89.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,136.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $2,005.29 | 2020-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,806.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,146.11 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $995.13 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Grifols USA, LLC | $828.82 | 2019-2025 | Xembify, Gamunex-C |
| Sanofi-Aventis U.S. LLC | $700.28 | 2020-2025 | |
| Genentech USA, INC. | $595.96 | 2019-2025 | Xolair |
| Kaleo, INC. | $551.59 | 2019-2024 | Auvi-Q |
| Amgen INC. | $533.65 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $455.18 | 2019-2025 | |
| Octapharma USA, INC. | $421.96 | 2019-2025 | Cutaquig, Octagam Immune Globulin (Human) |
| Genzyme Corporation | $349.59 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $296.72 | 2025 | Neffy |
| Pharming Healthcare, INC. | $288.43 | 2020-2025 | Ruconest |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Dinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.